AxoGen (AXGN) Stock Price, News & Analysis

Company Overview

AxoGen, Inc. is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue. These proprietary platforms are supported by a direct sales force in the United States and strategic distributor partnerships in international markets.

AxoGen markets its technologies across North America, Europe, Australia and parts of Latin America, collaborating with surgeons in specialties such as hand, orthopedics, plastic and reconstructive surgery. The company leverages clinical training programs, peer-reviewed research and reimbursement support services to drive adoption of its nerve repair solutions. As it advances its product pipeline, AxoGen continues to seek regulatory clearances and expand its global footprint in the evolving field of peripheral nerve repair.

Key Stats

• Today's Range: $38.16 to $40.29
• 50-Day Range: $30.78 to $43.74
• 52-Week Range: $9.22 to $45.83
• Volume: 428,357 shs
• Average Volume: 1.00 million shs
• Market Capitalization: $2.06 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.50
• Consensus Rating: Moderate Buy

AxoGen Stock Analysis - MarketRank™

AxoGen scored higher than 67% of companies evaluated by MarketBeat, and ranked 340th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AxoGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

AxoGen has a consensus price target of $46.50, representing about 19.9% upside from its current price of $38.78.

Amount of Analyst Coverage

AxoGen has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AxoGen are expected to grow in the coming year, from ($0.30) to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AxoGen is -61.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AxoGen is -61.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AxoGen has a P/B Ratio of 13.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.17% of the float of AxoGen has been sold short.

Short Interest Ratio / Days to Cover

AxoGen has a short interest ratio ("days to cover") of 4.07.

Change versus previous month

Short interest in AxoGen has recently decreased by 5.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AxoGen does not currently pay a dividend.

Dividend Growth

AxoGen does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.74

News Sentiment

AxoGen has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for AxoGen this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for AXGN on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,440,250.00 in company stock.

Percentage Held by Insiders

2.44% of the stock of AxoGen is held by insiders.

Percentage Held by Institutions

80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/28/2026
• Today: 6/01/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AXGN
• CIK: 805928
• Web: www.axogeninc.com
• Phone: (386) 462-6800
• Fax: 386-462-6801
• Employees: 450
• Year Founded: 2002

Price Target and Rating

• Average Price Target for AxoGen: $46.50
• High Price Target: $50.00
• Low Price Target: $36.00
• Potential Upside/Downside: +19.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.70 million
• Net Margins: -13.21%
• Pretax Margin: -13.21%
• Return on Equity: -9.63%
• Return on Assets: -6.26%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 7.10
• Quick Ratio: 5.33

Sales & Book Value

• Annual Sales: $225.21 million
• Price / Sales: 9.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.79 per share
• Price / Book: 13.90

Miscellaneous

• Outstanding Shares: 53,180,000
• Free Float: 51,880,000
• Market Cap: $2.06 billion
• Optionable: Optionable
• Beta: 1.12